Dendrimer-Based Drug Delivery: Recent Developments and Challenges

Abhijeet Deshpande ¹, Mrs. Pratiksha Jadhav², Mrs. Jisha Annie Geevarghese ³, Ana Khan ⁴, Firoj Tanwar ⁵

¹Assistant Professor, Department of Mechanical Engineering, Vishwakarma Institute of Technology, Pune, Maharashtra, 411037 Email ID : abhijeet.deshpande@vit.edu
²Asst. Professor, Dept. of Pharmacology Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth “Deemed to be University”, Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India panchashilanirmale@gmail.com Email ID : Mrs. Jisha Annie Geevarghese, ,
³Dept. of pharmacy Practice Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth “Deemed to be University”, Taluka-Karad, Dist-Satara, Pin-415 539, Maharashtra, India Email ID : kipjishaannie22@gmail.com
⁴Assistant Professor,School of Allied Health Sciences,Noida International University,Uttar Pradesh 203201,India. Email ID : ana.khan@niu.edu.in
⁵Assistant Professor, Department of Quality Assurance, Arya College of Pharmacy,Jaipur, Rajasthan, India. Email ID : firoj.tanwar@aryajaipur.com

ABSTRACT

In the past few years, dendrimer-based drug delivery systems have gotten a lot of attention because of their unique structure, which lets scientists precisely control how drugs are encapsulated, released, and targeted. These nanomaterials have a highly twisted, tree-like structure that lets them hold a lot of drugs, have their surfaces functionalised, and be able to target specific spots. This makes them perfect for making medicinal agents more effective and safer. Recent improvements to dendrimer-based drug delivery methods have focused on making them more stable, biocompatible, and able to cross biological boundaries, like the blood-brain barrier, so they can get to disease areas more effectively. One important area of progress is making dendrimers with different surface changes that make it easier to send drugs to specific cells or tissues. When targeting ligands like peptides, antibodies, and aptamers are attached to dendrimer surfaces, it has been shown that the selectivity can be improved and off-target effects can be reduced. Adding dendrimers to other nanoparticles, like liposomes or micelles, has also created mixed systems that take advantage of the best parts of multiple delivery platforms, making drug transport even more effective. Dendrimer-based drug administration has come a long way, but there are still some problems that need to be solved. There are problems with making dendrimers where the size, structure, and surface qualities can't be precisely controlled. They may also be poisonous because they have a lot of charged surfaces. Another problem is that making dendrimers on a large scale for business use is hard. Also, they need a lot of in vivo tests to see how safe and useful they are in the long run. It is important to solve these problems so that dendrimer-based systems can reach their full promise in clinical settings, especially for cancer therapy, gene transfer, and other focused medicines...

Keywords: Dendrimer-based drug delivery, nanostructures, targeted drug delivery, surface functionalization, biocompatibility, drug encapsulation.

How to cite this article: Deshpande A, Jadhav P, Geevarghese JA, Khan A, Tanwar F, Dendrimer-Based Drug Delivery: Recent Developments and Challenges .Int J Drug Deliv Technol. 2026;16(1s): 34-41; DOI: 10.25258/ijddt.16. 34-41